THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE
Clinical trials for THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE explained in plain language.
Never miss a new study
Get alerted when new THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE trials appear
Sign up with your email to follow new studies for THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to prevent deadly bleeding in unborn babies
Disease control Recruiting nowThis study tests a new medicine called nipocalimab against a standard treatment (IVIG) in 50 pregnant women whose babies are at risk for a rare condition that causes low platelets and severe bleeding. The goal is to see if nipocalimab can better prevent death or serious bleeding …
Matched conditions: THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug could shield unborn babies from deadly bleeding disorder
Disease control Recruiting nowThis study tests a drug called nipocalimab to see if it can prevent severe bleeding or death in unborn babies with a rare condition called FNAIT, where the mother's immune system attacks the baby's platelets. Pregnant women who have had a previous pregnancy affected by FNAIT are …
Matched conditions: THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 15, 2026 11:54 UTC